FDA approval of Akynzeo®

The U.S. Food & Drug Administration approves Helsinn's drug Akynzeo®

European Commission (EC) approved Akynzeo® in the European Union

European Commission (EC)  approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin‑based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union. 

News
Prev Next
News

June 25, 2015

Helsinn is delighted to be able to support this event at the leading congress for supportive ...

News

June 02, 2015

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27t...

News

June 01, 2015

Helsinn, the Swiss Group focused on building quality cancer care, announces today that its re...

News

May 27, 2015

The European approval of ALOXI® for paediatric use follows the FDA approval in May 2014 of AL...